

INDovation prog to incubate, commercialise Indian health start-ups

07 April 2022 | News

The prog was launched by Atal Innovation Mission, NITI Aayog, AGNli, FITT, IIT-Delhi, Pfizer and Social Alpha



Atal Innovation Mission, NITI Aayog, AGNli, Foundation for Innovation and Technology Transfer (FITT), IIT-Delhi, Pfizer and Social Alpha have launched the Pfizer INDovation Program to support breakthrough healthcare innovations by start-ups in India. Social Alpha is the core implementation partner responsible for executing the programme.

This is Version 2.0 of the Pfizer IIT-Delhi Innovation and IP Program and is one of Pfizer's CSR initiatives. In Version 1, Pfizer successfully incubated nine healthcare innovators and supported 19 IP filings. Now, in the first year of Version 2.0, three winning start-ups each in the areas of Oncology and Digital Health, will receive a grant of up to Rs 65 lakh each for product trials, pilot studies, and product market launches to accelerate the lab-to-market journey of their innovation.

AIM and NITI Aayog will provide the startups with access to their entire network of incubators and facilities via co-incubation and will also provide technical and strategic advisory to support to both the program and the startups. The Indian Institute of Technology, Delhi (IIT Delhi), will be the principal incubation partner while customised incubation support will be provided across technology incubation centres such as the IITs, other major technology institutes and the incubation network of Atal Innovation Mission across India. Social Alpha, as the implementation partner, will support start-ups to accelerate their lab-to-market journey.

The programme is also being supported by AGNli, PATH, AHPI, St Johns Research Institute, HCG Hospitals, Cytecure Hospitals, FICCI, UNHIEX, Google for Startups, Design Alpha, HIMSS, Marico Innovation Foundation, and TenX2.